ClinicalTrials.gg
CompletedNCT03345914Updated Aug 13, 2020Results posted

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

A Phase 3 interventional study of Dupilumab and Matching Placebo in Dermatitis, Atopic, sponsored by Regeneron Pharmaceuticals. Completed at 61 sites in 6 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2020-08-13.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
367
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
9th of 50
367 · median 75
Started
2017
with 3 others
Phase 3
11 of 50
none open now
Registered
20th of 50
by date
Lead sponsor
22 of 50
Regeneron Pharmaceuticals

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 9th largest by enrollment, is one of 4 that started in 2017, is one of 11 in phase 3, and was the 20th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The main objective of the trial is to demonstrate the efficacy of dupilumab administered concomitantly with topical corticosteroids (TCS) in participants ≥6 years to \<12 years of age with severe atopic dermatitis (AD).

The secondary objective is to assess the safety of dupilumab administered concomitantly with TCS in patients ≥6 years to \<12 years of age with severe AD.

03

Conditions studied

  • Dermatitis, Atopic

Keywords

  • Eczema
04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Diagnosis of AD according to the American Academy of Dermatology consensus criteria (Eichenfield 2003) at screening visit
  2. Chronic AD diagnosed at least 1 year prior to the screening visit
  3. IGA = 4 at screening and baseline visits
  4. EASI ≥21 at the screening and baseline visits
  5. BSA ≥15% at screening and baseline visits
  6. Documented recent history (within 6 months before the baseline visit) of inadequate response to topical AD medication(s)
  7. At least 11 (of a total of 14) applications of a stable dose of topical emollient (moisturizer) twice daily during the 7 consecutive days immediately before the baseline visit

Key Exclusion Criteria:

  1. Participation in a prior dupilumab clinical study
  2. Treatment with a systemic drug before the baseline visit
  3. Treatment with a topical investigational drug within 2 weeks prior to the baseline visit
  4. Treatment with crisabarole within 2 weeks prior to the baseline visit
  5. History of important side effects of medium potency topical (e.g, intolerance to treatment, reactions, significant skin atrophy, systemic effects), as assessed by the investigator or patient's treating physician
  6. Treatment with a topical calcineurin inhibitor (TCI) within 2 weeks prior to the baseline visit
  7. Having used any of the following treatments within 4 weeks before the baseline visit, or any condition that, in the opinion of the investigator, is likely to require such treatment(s) during the first 4 weeks of study treatment:

    1. /immunomodulating drugs (e.g, systemic corticosteroids, cyclosporine, mycophenolate-mofetil, interferon gamma, Janus kinase inhibitors, azathioprine, methotrexate, etc.)
    2. Phototherapy for AD
  8. Treatment with biologics, as follows:

    1. Any cell-depleting agents including but not limited to rituximab:

      within 6 months before the baseline visit, or until lymphocyte and CD 19+ lymphocyte count returns to normal, whichever is longer

    2. Other biologics: within 5 half-lives (if known) or 16 weeks before the baseline visit, whichever is longer
  9. Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit
  10. Body weight \<15 kg at baseline

Note: Other Inclusion/ Exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
367 participants (actual)

Study arms

  • Experimental
    Group 1

    Participants will receive dupilumab, dosing regimen 1

    Drug: Dupilumab · Other: Background Treatment: Topical Corticosteroids · Other: Background Treatment: Moisturizers

  • Experimental
    Group 2

    Participants will receive dupilumab, dosing regimen 2

    Drug: Dupilumab · Other: Background Treatment: Topical Corticosteroids · Other: Background Treatment: Moisturizers

  • Experimental
    Group 3

    Participants will receive matching placebo

    Drug: Matching Placebo · Other: Background Treatment: Topical Corticosteroids · Other: Background Treatment: Moisturizers

Interventions

  • Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous (SC)

    Also known as: DUPIXENT®, REGN668, SAR231893

  • DrugMatching Placebo

    Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous (SC)

  • OtherBackground Treatment: Topical Corticosteroids

    All participants are required to initiate treatment with a medium potency TCS using a standardized regimen. It is recommended that participants use triamcinolone acetonide 0.1% cream, fluocinolone acetonide 0.025% cream, or clobetasone butyrate 0.05%.

  • OtherBackground Treatment: Moisturizers

    All participants should apply moisturizers throughout the study. All types of moisturizers are permitted, but participants may not initiate treatment with prescription moisturizers. Participants may continue using stable doses of such moisturizers if initiated before the screening visit.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16

    The IGA was an assessment instrument used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 (clear) to 4 (severe). The full analysis set (FAS) included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at Week 16 were considered as a non-responder.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants With Eczema Area and Severity Index -75 (EASI-75) (≥ 75 Percent (%) Improvement From Baseline) at Week 16

    The EASI assesses severity and extent of atopic dermatitis (AD). Scores range from 0-72. Four AD disease characteristics (erythema, thickness, scratching, and lichenification) were assessed for severity on a scale of "0" (absent) through "3" (severe). Area of involvement assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder.

    Time frame: Week 16

  2. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16

    The EASI assesses severity and extent of AD. Scores range from 0-72. Four AD disease characteristics (erythema, thickness, scratching, and lichenification) were assessed for severity on a scale of "0" (absent) through "3" (severe). Area of involvement assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).

    Time frame: Baseline (Day 1), Week 16

  3. Percent Change From Baseline in Weekly Average of Daily Worst Itch Score at Week 16

    The worst itch scale was a simple assessment tool that participants used to report the intensity of their pruritus (itch). This was an 11-point scale (0 to 10) in which 0 indicated no itching while 10 indicated worst itching possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, and follow-up period). The daily worst itch score was calculated as the worse of the scores for the 2 questions. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).

    Time frame: Baseline (Day 1), Week 16

  4. Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Itch Score ≥3 Points at Week 16

    The worst itch scale was a simple assessment tool that participants used to report the intensity of their pruritus (itch). This was an 11-point scale (0 to 10) in which 0 indicated no itching while 10 indicated worst itching possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, and follow-up period). The daily worst itch score was calculated as the worse of the scores for the 2 questions. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder. Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint.

    Time frame: Week 16

  5. Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Itch Score ≥4 Points at Week 16

    The worst itch scale was a simple assessment tool that participants used to report the intensity of their pruritus (itch). This was an 11-point scale (0 to 10) in which 0 indicated no itching while 10 indicated worst itching possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, and follow-up period). The daily worst itch score was calculated as the worse of the scores for the 2 questions. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder. Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint.

    Time frame: Week 16

  6. Percentage of Participants Achieving Eczema Area and Severity Index - 50 (EASI-50) (≥ 50% Improvement From Baseline) at Week 16

    The EASI assessed severity and extent of AD. Scores range from 0-72. Four AD disease characteristics (erythema, thickness, scratching, and lichenification) were assessed for severity on a scale of "0" (absent) through "3" (severe). Area of involvement assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder.

    Time frame: Week 16

  7. Percentage of Participants Achieving Eczema Area and Severity Index - 90 (EASI - 90) (≥ 90% Improvement From Baseline) at Week 16

    The EASI assessed the severity and extent of atopic dermatitis (AD). Scores range from 0-72. Four AD disease characteristics (erythema, thickness, scratching, and lichenification) were assessed for severity on a scale of "0" (absent) through "3" (severe). Area of involvement assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder.

    Time frame: Week 16

  8. Time to Achieve ≥ 4 Point Reduction of Weekly Average of Daily Worst Itch Score From Baseline During the 16-week Treatment Period

    The worst itch scale: simple assessment tool that participants used to report intensity of their pruritus (itch). This was an 11-point scale (0 to 10) where 0 (no itching) and 10 (worst itching) possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, \& follow-up period). The daily worst itch score was calculated as worse of scores for 2 questions. FAS was used. Time to event is calculated in weeks as (date of first event - date of first dose)/7. The event of NRS reduction ≥ 4 was based on observed data without setting data to be non-responder after rescue treatment use. Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint \& "NA" represents "Not computable" as only 12.3% of participants achieved NRS reduction during 16-week treatment period \& hence median time to achieve ≥ 4-point reduction of NRS for placebo +TCS treated participants could not be reported.

    Time frame: Baseline (Day 1) up to Week 16

  9. Time to Achieve ≥ 3 Point Reduction of Weekly Average of Daily Worst Itch Score From Baseline During the 16-week Treatment Period

    The worst itch scale: a simple assessment tool that participants used to report intensity of their pruritus (itch). This was an 11-point scale (0 to 10) where 0 (no itching) \& 10 (worst itching) possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, \& follow-up period). Daily worst itch score was calculated as worse of scores for 2 questions. FAS was used. Time to event is calculated in weeks as (date of first event - date of first dose)/7. The event of NRS reduction ≥ 3 was based on observed data without setting data to be non-responder after rescue treatment use. Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint \& "NA" represents "Not computable" as only 21.1% of participants achieved NRS reduction during 16-week treatment period \& hence median time to achieve ≥ 3-point reduction of NRS for placebo +TCS treated participants could not be reported.

    Time frame: Baseline (Day 1) up to Week 16

  10. Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 16

    BSA affected by AD was assessed for each section of the body using the rule of nines (the possible highest score for each region is: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and were reported as a percentage of all major body sections combined. The proportion assigned to different body regions were different in younger children as compared to older children (head and neck area is assigned a higher proportion in younger children as compared to older children). The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).

    Time frame: Baseline (Day 1), Week 16

  11. Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16

    SCORAD was used to assess the extent and severity of AD. Extent and severity of eczema as well as subjective symptoms (insomnia, etc) were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease). The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).

    Time frame: Baseline (Day 1), Week 16

  12. Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16

    CDLQI was a validated 10 question tool to measure the impact of skin disease on the quality of life (QOL) in children by assessing how much the skin problem has affected the participant over the past week. Nine questions were scored as follows: Very much = 3, Quite a lot = 2, Only a little = 1, Not at all or unanswered = 0. Question 7 has an added possible response, which was scored as 3. CDLQI equals the sum of the score of each question (maximum = 30, minimum = 0). Higher the score, the greater the impact on QOL. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Data presented reflects the mean \& standard deviation of the CDLQI total scores.

    Time frame: Baseline (Day 1), Week 16

  13. Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16

    POEM was a 7-item, validated questionnaire used to assess disease symptoms in children and adults. The format was a response to 7 items (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) based on frequency of these disease symptoms during the past week (ie, 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days) with a scoring system of 0 to 28; the total score reflected the disease-related morbidity. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). A high score is indicative of a poor quality of life.

    Time frame: Baseline (Day 1), Week 16

  14. Change From Baseline in Weekly Average of Daily Worst Itch Score at Week 16

    The worst itch scale was a simple assessment tool that participants used to report the intensity of their pruritus (itch). This was an 11-point scale (0 to 10) in which 0 indicated no itching while 10 indicated worst itching possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, and follow-up period). The daily worst itch score was calculated as the worse of the scores for the 2 questions. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).

    Time frame: Baseline (Day 1), Week 16

  15. Change From Baseline in Dermatitis Family Index (DFI) at Week 16

    DFI was a 10-item questionnaire with items inquiring about housework, food preparation, sleep, family leisure activity, shopping, expenditure, tiredness, emotional distress, relationships and the impact of helping with treatment on the primary caregiver's life. The DFI questions were scored on a four-point Likert scale ranging from 0 to 3, so that the total DFI score ranges from 0 to 30. Timeframe of reference was the past week. A higher DFI score indicated greater impairment in family Quality of life (QOL) as affected by atopic dermatitis. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).

    Time frame: Baseline (Day 1) , Week 16

  16. Change From Baseline in Patient Reported Outcomes Measurements Information Systems (PROMIS) Pediatric Anxiety Short Form Scale Total Score at Week 16

    PROMIS Anxiety instrument measures self-reported fear (fearfulness, panic), anxious misery (worry, dread), hyperarousal (tension, nervousness, restlessness), \& somatic symptoms related to arousal (racing heart, dizziness). Each question has 5 response options ranging in value from 1-5 (1=Never, 2=Almost never, 3=Sometimes, 4=Often, 5=Almost Always). Total raw score calculated using sum of response values: for 8-item form, lowest possible is 8 \& highest possible is 40; For 6-item form: lowest possible is 6; highest possible is 30. Higher score indicates greater severity of symptoms.

    Time frame: Baseline (Day 1), Week 16

  17. Change From Baseline in Patient Reported Outcomes Measurements Information Systems (PROMIS) Pediatric Depressive Symptoms Short Form Scale Score at Week 16

    PROMIS Depression instrument assesses self-reported negative mood (sadness/guilt), views of self (self-criticism/worthlessness) \& social cognition (loneliness/interpersonal alienation), \& decreased positive affect \& engagement (loss of interest/meaning/purpose). Each question has 5 response options with values from 1-5 (1=Never, 2=Almost never, 3=Sometimes, 4=Often, 5=Almost Always). Total raw score is the sum of response values. For 8-item form, lowest possible is 8, highest is 40; for 6-item form, lowest possible is 6, highest is 30. Higher score indicates greater severity of symptoms.

    Time frame: Baseline (Day 1), Week 16

  18. Percentage of Participants Having at Least One Skin Infection Treatment Emergent Adverse Event (TEAE) (Excluding Herpetic Infections) Through Week 16

    Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to the end of study. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-subjects hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. Percentage of participants having at least one skin infection TEAE (Excluding Herpetic Infections) through Week 16 were reported. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).

    Time frame: Baseline through Week 16

  19. Percentage of Participants Having at Least One Serious Treatment Emergent Adverse Event (TEAE) Through Week 16

    Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to the end of study. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-participants hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).

    Time frame: Baseline (Day 1) through Week 16

  20. Proportion of Topical Corticosteroid (TCS) Medication-free Days From Baseline to Week 16

    Proportion of TCS medication-free days is calculated as the number of days that a participant used neither TCS/TCI nor system rescue therapy divided by the study days of each period. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint.

    Time frame: Baseline (Day 1), Week 16

  21. Mean Weekly Dose of Topical Corticosteroid (TCS) in Grams for Low or Medium Potency TCS From Baseline to Week 16

    Mean weekly dose of TCS in grams for low or medium potency TCS from baseline to Week 16 were reported. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint.

    Time frame: Baseline (Day 1), Week 16

07

Results

Posted Aug 13, 2020

Participant flow

A total of 474 participants were screened for study eligibility at multiple sites in the United States and Europe. Screen failure was mostly due to inclusion/exclusion criteria not met and "other" reasons. The majority of participants (221/367) were enrolled at study sites in the United States.

Participant flow — Overall Study
MilestonePlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Started123122122
Completed week 16 study treatment114118119
Completed week 28 end of study000
Completed000
Not completed123122122
Withdrew: Transition to another study at week 16808678
Withdrew: Transition to ole during follow-up373339
Withdrew: Physician decision011
Withdrew: Withdrawal by subject512
Withdrew: Other111
Withdrew: Ongoing001

Outcome measures

PrimaryPercentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16

The IGA was an assessment instrument used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 (clear) to 4 (severe). The full analysis set (FAS) included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at Week 16 were considered as a non-responder.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16
Percentage of ParticipantsPlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 1611.432.829.5
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · Cochran-Mantel-Haenszel · p = = 0.0004 (The Cochran-Mantel-Haenszel (CMH) test adjusted by randomization strata (baseline weight group (\< 30 kilograms (kg) or ≥ 30 kg) and region (North America or Europe) was used for the analysis of percentage of participants with IGA 0 or 1 at Week 16.) · Percentage difference: 18.1 · 95% CI 8.28 to 27.97
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (The Cochran-Mantel-Haenszel (CMH) test adjusted by randomization strata (baseline weight group (\< 30 kg or ≥ 30 kg) and region (North America or Europe) was used for the analysis of percentage of participants with IGA 0 or 1 at Week 16.) · Percentage difference: 21.4 · 95% CI 11.36 to 31.45
SecondaryPercentage of Participants With Eczema Area and Severity Index -75 (EASI-75) (≥ 75 Percent (%) Improvement From Baseline) at Week 16

The EASI assesses severity and extent of atopic dermatitis (AD). Scores range from 0-72. Four AD disease characteristics (erythema, thickness, scratching, and lichenification) were assessed for severity on a scale of "0" (absent) through "3" (severe). Area of involvement assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Eczema Area and Severity Index -75 (EASI-75) (≥ 75 Percent (%) Improvement From Baseline) at Week 16
Percentage of ParticipantsPlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Percentage of Participants With Eczema Area and Severity Index -75 (EASI-75) (≥ 75 Percent (%) Improvement From Baseline) at Week 1626.869.767.2
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (The Cochran-Mantel-Haenszel (CMH) test adjusted by randomization strata (baseline weight group (\< 30 kg or ≥ 30 kg) and region (North America or Europe) was used for the analysis of percentage of participants with EASI-75 at Week 16.) · Percentage difference: 40.4 · 95% CI 28.95 to 51.82
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (The Cochran-Mantel-Haenszel (CMH) test adjusted by randomization strata (baseline weight group (\< 30 kg or ≥ 30 kg) and region (North America or Europe) was used for the analysis of percentage of participants with EASI-75 at Week 16.) · Percentage difference: 42.8 · 95% CI 31.54 to 54.15
SecondaryPercent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16

The EASI assesses severity and extent of AD. Scores range from 0-72. Four AD disease characteristics (erythema, thickness, scratching, and lichenification) were assessed for severity on a scale of "0" (absent) through "3" (severe). Area of involvement assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).

Time frame:
Baseline (Day 1), Week 16
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16
Percent changePlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16-48.6 ± 2.46-82.1 ± 2.37-78.4 ± 2.35
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · ANCOVA · p = < 0.0001 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -29.8 · 95% CI -36.33 to -23.24
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -33.4 · 95% CI -40.06 to -26.82
SecondaryPercent Change From Baseline in Weekly Average of Daily Worst Itch Score at Week 16

The worst itch scale was a simple assessment tool that participants used to report the intensity of their pruritus (itch). This was an 11-point scale (0 to 10) in which 0 indicated no itching while 10 indicated worst itching possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, and follow-up period). The daily worst itch score was calculated as the worse of the scores for the 2 questions. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).

Time frame:
Baseline (Day 1), Week 16
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Weekly Average of Daily Worst Itch Score at Week 16
Percent changePlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Percent Change From Baseline in Weekly Average of Daily Worst Itch Score at Week 16-25.9 ± 2.90-54.6 ± 2.89-57.0 ± 2.77
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · ANCOVA · p = < 0.0001 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -31 · 95% CI -38.76 to -23.26
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -28.6 · 95% CI -36.47 to -20.82
SecondaryPercentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Itch Score ≥3 Points at Week 16

The worst itch scale was a simple assessment tool that participants used to report the intensity of their pruritus (itch). This was an 11-point scale (0 to 10) in which 0 indicated no itching while 10 indicated worst itching possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, and follow-up period). The daily worst itch score was calculated as the worse of the scores for the 2 questions. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder. Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Itch Score ≥3 Points at Week 16
Percentage of ParticipantsPlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Itch Score ≥3 Points at Week 1621.160.367.5
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (P-values were derived by Cochran-Mantel-Haenszel (CMH) test stratified by region \[North America vs Europe\] and baseline weight group \[\< 30 kg vs ≥ 30 kg\].) · Percentage difference: 46.4 · 95% CI 35.3 to 57.42
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (P-values were derived by Cochran-Mantel-Haenszel (CMH) test stratified by region \[North America vs Europe\] and baseline weight group \[\< 30 kg vs ≥ 30 kg\].) · Percentage difference: 39.2 · 95% CI 27.88 to 50.51
SecondaryPercentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Itch Score ≥4 Points at Week 16

The worst itch scale was a simple assessment tool that participants used to report the intensity of their pruritus (itch). This was an 11-point scale (0 to 10) in which 0 indicated no itching while 10 indicated worst itching possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, and follow-up period). The daily worst itch score was calculated as the worse of the scores for the 2 questions. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder. Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Itch Score ≥4 Points at Week 16
Percentage of ParticipantsPlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Itch Score ≥4 Points at Week 1612.350.858.3
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (P-values were derived by Cochran-Mantel-Haenszel (CMH) test stratified by region \[North America vs Europe\] and baseline weight group \[\< 30 kg vs ≥ 30 kg\].) · Percentage difference: 46 · 95% CI 35.47 to 56.61
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (P-values were derived by Cochran-Mantel-Haenszel (CMH) test stratified by region \[North America vs Europe\] and baseline weight group \[\< 30 kg vs ≥ 30 kg\].) · Percentage difference: 38.5 · 95% CI 27.86 to 49.21
SecondaryPercentage of Participants Achieving Eczema Area and Severity Index - 50 (EASI-50) (≥ 50% Improvement From Baseline) at Week 16

The EASI assessed severity and extent of AD. Scores range from 0-72. Four AD disease characteristics (erythema, thickness, scratching, and lichenification) were assessed for severity on a scale of "0" (absent) through "3" (severe). Area of involvement assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Eczema Area and Severity Index - 50 (EASI-50) (≥ 50% Improvement From Baseline) at Week 16
Percentage of ParticipantsPlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Percentage of Participants Achieving Eczema Area and Severity Index - 50 (EASI-50) (≥ 50% Improvement From Baseline) at Week 1643.191.082.8
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (P-values were derived by Cochran-Mantel-Haenszel (CMH) test stratified by region \[North America vs Europe\] and baseline weight group \[\< 30 kg vs ≥ 30 kg\].) · Percentage difference: 39.7 · 95% CI 28.68 to 50.72
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (P-values were derived by Cochran-Mantel-Haenszel (CMH) test stratified by region \[North America vs Europe\] and baseline weight group \[\< 30 kg vs ≥ 30 kg\].) · Percentage difference: 47.9 · 95% CI 37.77 to 58.01
SecondaryPercentage of Participants Achieving Eczema Area and Severity Index - 90 (EASI - 90) (≥ 90% Improvement From Baseline) at Week 16

The EASI assessed the severity and extent of atopic dermatitis (AD). Scores range from 0-72. Four AD disease characteristics (erythema, thickness, scratching, and lichenification) were assessed for severity on a scale of "0" (absent) through "3" (severe). Area of involvement assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Eczema Area and Severity Index - 90 (EASI - 90) (≥ 90% Improvement From Baseline) at Week 16
Percentage of ParticipantsPlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Percentage of Participants Achieving Eczema Area and Severity Index - 90 (EASI - 90) (≥ 90% Improvement From Baseline) at Week 167.341.830.3
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (P-values were derived by Cochran-Mantel-Haenszel (CMH) test stratified by region \[North America vs Europe\] and baseline weight group \[\< 30 kg vs ≥ 30 kg\].) · Percentage difference: 23 · 95% CI 13.65 to 32.38
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (P-values were derived by Cochran-Mantel-Haenszel (CMH) test stratified by region \[North America vs Europe\] and baseline weight group \[\< 30 kg vs ≥ 30 kg\].) · Percentage difference: 34.5 · 95% CI 24.6 to 44.37
SecondaryTime to Achieve ≥ 4 Point Reduction of Weekly Average of Daily Worst Itch Score From Baseline During the 16-week Treatment Period

The worst itch scale: simple assessment tool that participants used to report intensity of their pruritus (itch). This was an 11-point scale (0 to 10) where 0 (no itching) and 10 (worst itching) possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, \& follow-up period). The daily worst itch score was calculated as worse of scores for 2 questions. FAS was used. Time to event is calculated in weeks as (date of first event - date of first dose)/7. The event of NRS reduction ≥ 4 was based on observed data without setting data to be non-responder after rescue treatment use. Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint \& "NA" represents "Not computable" as only 12.3% of participants achieved NRS reduction during 16-week treatment period \& hence median time to achieve ≥ 4-point reduction of NRS for placebo +TCS treated participants could not be reported.

Time frame:
Baseline (Day 1) up to Week 16
Reported as:
Median · Weeks
Time to Achieve ≥ 4 Point Reduction of Weekly Average of Daily Worst Itch Score From Baseline During the 16-week Treatment Period
WeeksPlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Time to Achieve ≥ 4 Point Reduction of Weekly Average of Daily Worst Itch Score From Baseline During the 16-week Treatment PeriodNA (NA to NA)10.0 (7 to 13)10.0 (8 to 12)
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · Cox model · p = < 0.0001 (P-values were derived by Cochran-Mantel-Haenszel (CMH) test stratified by region \[North America vs Europe\] and baseline weight group \[\< 30 kg vs ≥ 30 kg\].) · Hazard ratios: 3.114 · 95% CI 2.097 to 4.624
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · Cox model · p = < 0.0001 (P-values were derived by Cochran-Mantel-Haenszel (CMH) test stratified by region \[North America vs Europe\] and baseline weight group \[\< 30 kg vs ≥ 30 kg\].) · Hazard ratios: 2.921 · 95% CI 1.957 to 4.36
SecondaryTime to Achieve ≥ 3 Point Reduction of Weekly Average of Daily Worst Itch Score From Baseline During the 16-week Treatment Period

The worst itch scale: a simple assessment tool that participants used to report intensity of their pruritus (itch). This was an 11-point scale (0 to 10) where 0 (no itching) \& 10 (worst itching) possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, \& follow-up period). Daily worst itch score was calculated as worse of scores for 2 questions. FAS was used. Time to event is calculated in weeks as (date of first event - date of first dose)/7. The event of NRS reduction ≥ 3 was based on observed data without setting data to be non-responder after rescue treatment use. Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint \& "NA" represents "Not computable" as only 21.1% of participants achieved NRS reduction during 16-week treatment period \& hence median time to achieve ≥ 3-point reduction of NRS for placebo +TCS treated participants could not be reported.

Time frame:
Baseline (Day 1) up to Week 16
Reported as:
Median · Weeks
Time to Achieve ≥ 3 Point Reduction of Weekly Average of Daily Worst Itch Score From Baseline During the 16-week Treatment Period
WeeksPlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Time to Achieve ≥ 3 Point Reduction of Weekly Average of Daily Worst Itch Score From Baseline During the 16-week Treatment PeriodNA (11 to NA)6.0 (5 to 9)5.0 (5 to 7)
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · Cox model · p = < 0.0001 (P-values were derived by Cochran-Mantel-Haenszel (CMH) test stratified by region \[North America vs Europe\] and baseline weight group \[\< 30 kg vs ≥ 30 kg\].) · Hazard ratios: 2.278 · 95% CI 1.631 to 3.182
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · Cox model · p = < 0.0001 (P-values were derived by Cochran-Mantel-Haenszel (CMH) test stratified by region \[North America vs Europe\] and baseline weight group \[\< 30 kg vs ≥ 30 kg\].) · Hazard ratios: 2.075 · 95% CI 1.481 to 2.908
SecondaryChange From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 16

BSA affected by AD was assessed for each section of the body using the rule of nines (the possible highest score for each region is: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and were reported as a percentage of all major body sections combined. The proportion assigned to different body regions were different in younger children as compared to older children (head and neck area is assigned a higher proportion in younger children as compared to older children). The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).

Time frame:
Baseline (Day 1), Week 16
Reported as:
Least squares mean · Percentage of BSA
Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 16
Percentage of BSAPlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 16-21.65 ± 1.721-40.53 ± 1.648-39.37 ± 1.629
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · ANCOVA · p = < 0.0001 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -17.72 · 95% CI -22.272 to -13.161
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -18.88 · 95% CI -23.479 to -14.289
SecondaryPercent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16

SCORAD was used to assess the extent and severity of AD. Extent and severity of eczema as well as subjective symptoms (insomnia, etc) were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease). The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).

Time frame:
Baseline (Day 1), Week 16
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16
Percent changePlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16-29.8 ± 2.26-62.4 ± 2.13-60.2 ± 2.11
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · ANCOVA · p = < 0.0001 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -30.4 · 95% CI -36.3 to -24.48
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -32.6 · 95% CI -38.57 to -26.59
SecondaryChange From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16

CDLQI was a validated 10 question tool to measure the impact of skin disease on the quality of life (QOL) in children by assessing how much the skin problem has affected the participant over the past week. Nine questions were scored as follows: Very much = 3, Quite a lot = 2, Only a little = 1, Not at all or unanswered = 0. Question 7 has an added possible response, which was scored as 3. CDLQI equals the sum of the score of each question (maximum = 30, minimum = 0). Higher the score, the greater the impact on QOL. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Data presented reflects the mean \& standard deviation of the CDLQI total scores.

Time frame:
Baseline (Day 1), Week 16
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16
Score on a ScalePlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16-6.4 ± 0.51-10.6 ± 0.47-10.7 ± 0.46
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · ANCOVA · p = < 0.0001 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -4.3 · 95% CI -5.62 to -2.99
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (The confidence interval (CI) with p-value was based on treatment difference (dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -4.2 · 95% CI -5.57 to -2.89
SecondaryChange From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16

POEM was a 7-item, validated questionnaire used to assess disease symptoms in children and adults. The format was a response to 7 items (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) based on frequency of these disease symptoms during the past week (ie, 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days) with a scoring system of 0 to 28; the total score reflected the disease-related morbidity. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). A high score is indicative of a poor quality of life.

Time frame:
Baseline (Day 1), Week 16
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16
Score on a ScalePlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16-5.3 ± 0.69-13.6 ± 0.65-13.4 ± 0.65
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · ANCOVA · p = < 0.0001 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -8.1 · 95% CI -9.96 to -6.31
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -8.3 · 95% CI -10.13 to -6.43
SecondaryChange From Baseline in Weekly Average of Daily Worst Itch Score at Week 16

The worst itch scale was a simple assessment tool that participants used to report the intensity of their pruritus (itch). This was an 11-point scale (0 to 10) in which 0 indicated no itching while 10 indicated worst itching possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, and follow-up period). The daily worst itch score was calculated as the worse of the scores for the 2 questions. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).

Time frame:
Baseline (Day 1), Week 16
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Weekly Average of Daily Worst Itch Score at Week 16
Score on a ScalePlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Change From Baseline in Weekly Average of Daily Worst Itch Score at Week 16-2.05 ± 0.215-4.22 ± 0.207-4.45 ± 0.206
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · ANCOVA · p = < 0.0001 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -2.41 · 95% CI -2.984 to -1.831
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -2.18 · 95% CI -2.754 to -1.599
SecondaryChange From Baseline in Dermatitis Family Index (DFI) at Week 16

DFI was a 10-item questionnaire with items inquiring about housework, food preparation, sleep, family leisure activity, shopping, expenditure, tiredness, emotional distress, relationships and the impact of helping with treatment on the primary caregiver's life. The DFI questions were scored on a four-point Likert scale ranging from 0 to 3, so that the total DFI score ranges from 0 to 30. Timeframe of reference was the past week. A higher DFI score indicated greater impairment in family Quality of life (QOL) as affected by atopic dermatitis. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).

Time frame:
Baseline (Day 1) , Week 16
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Dermatitis Family Index (DFI) at Week 16
Score on a ScalePlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Change From Baseline in Dermatitis Family Index (DFI) at Week 16-6.77 ± 0.497-10.75 ± 0.476-10.89 ± 0.469
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · ANCOVA · p = < 0.0001 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -4.11 · 95% CI -5.434 to -2.796
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -3.98 · 95% CI -5.298 to -2.657
SecondaryChange From Baseline in Patient Reported Outcomes Measurements Information Systems (PROMIS) Pediatric Anxiety Short Form Scale Total Score at Week 16

PROMIS Anxiety instrument measures self-reported fear (fearfulness, panic), anxious misery (worry, dread), hyperarousal (tension, nervousness, restlessness), \& somatic symptoms related to arousal (racing heart, dizziness). Each question has 5 response options ranging in value from 1-5 (1=Never, 2=Almost never, 3=Sometimes, 4=Often, 5=Almost Always). Total raw score calculated using sum of response values: for 8-item form, lowest possible is 8 \& highest possible is 40; For 6-item form: lowest possible is 6; highest possible is 30. Higher score indicates greater severity of symptoms.

Time frame:
Baseline (Day 1), Week 16
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Patient Reported Outcomes Measurements Information Systems (PROMIS) Pediatric Anxiety Short Form Scale Total Score at Week 16
Score on a ScalePlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Change From Baseline in Patient Reported Outcomes Measurements Information Systems (PROMIS) Pediatric Anxiety Short Form Scale Total Score at Week 16-10.17 ± 0.912-13.19 ± 0.861-13.54 ± 0.860
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · ANCOVA · p = = 0.0061 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -3.37 · 95% CI -5.779 to -0.962
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · ANCOVA · p = = 0.0133 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -3.02 · 95% CI -5.414 to -0.629
SecondaryChange From Baseline in Patient Reported Outcomes Measurements Information Systems (PROMIS) Pediatric Depressive Symptoms Short Form Scale Score at Week 16

PROMIS Depression instrument assesses self-reported negative mood (sadness/guilt), views of self (self-criticism/worthlessness) \& social cognition (loneliness/interpersonal alienation), \& decreased positive affect \& engagement (loss of interest/meaning/purpose). Each question has 5 response options with values from 1-5 (1=Never, 2=Almost never, 3=Sometimes, 4=Often, 5=Almost Always). Total raw score is the sum of response values. For 8-item form, lowest possible is 8, highest is 40; for 6-item form, lowest possible is 6, highest is 30. Higher score indicates greater severity of symptoms.

Time frame:
Baseline (Day 1), Week 16
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Patient Reported Outcomes Measurements Information Systems (PROMIS) Pediatric Depressive Symptoms Short Form Scale Score at Week 16
Score on a ScalePlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Change From Baseline in Patient Reported Outcomes Measurements Information Systems (PROMIS) Pediatric Depressive Symptoms Short Form Scale Score at Week 16-7.42 ± 0.848-12.84 ± 0.793-11.92 ± 0.790
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · ANCOVA · p = < 0.0001 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -4.5 · 95% CI -6.734 to -2.272
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANCOVA model with baseline measurement as covariate and the treatment, randomization strata as fixed factors.) · Least square mean difference: -5.42 · 95% CI -7.641 to -3.207
SecondaryPercentage of Participants Having at Least One Skin Infection Treatment Emergent Adverse Event (TEAE) (Excluding Herpetic Infections) Through Week 16

Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to the end of study. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-subjects hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. Percentage of participants having at least one skin infection TEAE (Excluding Herpetic Infections) through Week 16 were reported. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).

Time frame:
Baseline through Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Having at Least One Skin Infection Treatment Emergent Adverse Event (TEAE) (Excluding Herpetic Infections) Through Week 16
Percentage of ParticipantsPlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Percentage of Participants Having at Least One Skin Infection Treatment Emergent Adverse Event (TEAE) (Excluding Herpetic Infections) Through Week 1613.05.78.2
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · Cochran-Mantel-Haenszel · p = = 0.222 (P-values were derived by Cochran-Mantel-Haenszel (CMH) test stratified by region \[North America vs Europe\] and baseline weight group \[\< 30 kg vs ≥ 30 kg\].) · Percentage differenece: -4.8 · 95% CI -12.49 to 2.87
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · Cochran-Mantel-Haenszel · p = = 0.0508 (P-values were derived by Cochran-Mantel-Haenszel (CMH) test stratified by region \[North America vs Europe\] and baseline weight group \[\< 30 kg vs ≥ 30 kg\].) · Percentage differenece: -7.3 · 95% CI -14.51 to -0.03
SecondaryPercentage of Participants Having at Least One Serious Treatment Emergent Adverse Event (TEAE) Through Week 16

Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to the end of study. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-participants hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).

Time frame:
Baseline (Day 1) through Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Having at Least One Serious Treatment Emergent Adverse Event (TEAE) Through Week 16
Percentage of ParticipantsPlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Percentage of Participants Having at Least One Serious Treatment Emergent Adverse Event (TEAE) Through Week 161.61.60
SecondaryProportion of Topical Corticosteroid (TCS) Medication-free Days From Baseline to Week 16

Proportion of TCS medication-free days is calculated as the number of days that a participant used neither TCS/TCI nor system rescue therapy divided by the study days of each period. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint.

Time frame:
Baseline (Day 1), Week 16
Reported as:
Mean · Proportion of Days
Proportion of Topical Corticosteroid (TCS) Medication-free Days From Baseline to Week 16
Proportion of DaysPlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Proportion of Topical Corticosteroid (TCS) Medication-free Days From Baseline to Week 160.11 ± 0.1850.20 ± 0.2300.19 ± 0.207
SecondaryMean Weekly Dose of Topical Corticosteroid (TCS) in Grams for Low or Medium Potency TCS From Baseline to Week 16

Mean weekly dose of TCS in grams for low or medium potency TCS from baseline to Week 16 were reported. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint.

Time frame:
Baseline (Day 1), Week 16
Reported as:
Least squares mean · Grams
Mean Weekly Dose of Topical Corticosteroid (TCS) in Grams for Low or Medium Potency TCS From Baseline to Week 16
GramsPlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Mean Weekly Dose of Topical Corticosteroid (TCS) in Grams for Low or Medium Potency TCS From Baseline to Week 1620.1 ± 1.3715.0 ± 1.3614.4 ± 1.38
Statistical analysis
  • Placebo + TCS vs Dupilumab 100 mg or 200 mg Q2W + TCS · ANOVA · p = = 0.003 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANOVA model with the treatment, randomization strata as fixed factors.) · Least square mean difference: -5.7 · 95% CI -9.49 to -1.96
  • Placebo + TCS vs Dupilumab 300 mg Q4W + TCS · ANOVA · p = = 0.0082 (The confidence interval (CI) with p-value was based on treatment difference (Dupilumab group vs placebo) of the LS mean percent change using ANOVA model with the treatment, randomization strata as fixed factors.) · Least square mean difference: -5.1 · 95% CI -8.8 to -1.31

Adverse events

Collected over Reported AEs are treatment-emergent adverse events which were collected for both the 16-week treatment period and the follow-up period for as long as 12 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + TCS0/120 (0%)2/120 (1.7%)57/120 (47.5%)
Dupilumab 300 mg Q4W + TCS0/120 (0%)3/120 (2.5%)47/120 (39.2%)
Dupilumab 100 mg or 200 mg Q2W + TCS0/122 (0%)0/122 (0%)50/122 (41%)
Most frequent serious events
Most frequent serious events
EventPlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Food allergyImmune system disorders0/1201/1200/122
Urinary tract infectionInfections and infestations0/1201/1200/122
Bone contusionInjury, poisoning and procedural complications0/1201/1200/122
AsthmaRespiratory, thoracic and mediastinal disorders1/1200/1200/122
Dermatitis atopicSkin and subcutaneous tissue disorders1/1200/1200/122
Most frequent other events
Most frequent other events
EventPlacebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCS
Dermatitis atopicSkin and subcutaneous tissue disorders17/1208/12010/122
NasopharyngitisInfections and infestations8/12015/1208/122
Upper respiratory tract infectionInfections and infestations12/12014/12012/122
AsthmaRespiratory, thoracic and mediastinal disorders11/1202/1204/122
HeadacheNervous system disorders10/1206/1207/122
CoughRespiratory, thoracic and mediastinal disorders9/1203/1205/122
VomitingGastrointestinal disorders8/1206/1206/122
Injection site erythemaGeneral disorders2/1205/1207/122
ConjunctivitisInfections and infestations3/1205/1207/122
Viral upper respiratory tract infectionInfections and infestations6/1202/1201/122

Baseline characteristics

The full analysis set (FAS) includes all randomized participants.

Age, Continuous
Age, Continuous(years)Placebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCSTotal
Mean8.3 ± 1.768.5 ± 1.748.5 ± 1.688.5 ± 1.72
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCSTotal
Female626557184
Male615765183
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCSTotal
Hispanic or Latino13161645
Not Hispanic or Latino110106106322
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCSTotal
American Indian or Alaska Native0000
Asian1351028
Native Hawaiian or Other Pacific Islander0000
Black or African American23192062
White778988254
More than one race0000
Unknown or Not Reported109423
Eczema Area and Severity Index (EASI) Score
Eczema Area and Severity Index (EASI) Score(Score on a Scale)Placebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCSTotal
Mean39.0 ± 12.0137.4 ± 12.4537.3 ± 10.8637.9 ± 11.79
Investigator's Global Assessment (IGA) Score
Investigator's Global Assessment (IGA) Score(Score on a Scale)Placebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCSTotal
Mean4.0 ± 0.004.0 ± 0.094.0 ± 0.004.0 ± 0.05
Weekly Average of Daily Worst Itch Score
Weekly Average of Daily Worst Itch Score(Score on a Scale)Placebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCSTotal
Mean7.7 ± 1.547.8 ± 1.587.8 ± 1.527.8 ± 1.54
Body Surface Area (BSA) of Atopic Dermatitis
Body Surface Area (BSA) of Atopic Dermatitis(Percentage of BSA)Placebo + TCSDupilumab 300 mg Q4W + TCSDupilumab 100 mg or 200 mg Q2W + TCSTotal
Mean60.2 ± 21.4654.8 ± 21.5857.8 ± 20.0457.6 ± 21.10

6 further baseline measures are reported on the registry.

08

Study locations

61 sites
  • Regeneron Research Site
    Birmingham, Alabama 35209, United States
  • Regeneron Research Site
    Gilbert, Arizona 85234, United States
  • Regeneron Research Site
    Bakersfield, California 93309, United States
  • Regeneron Research Site
    Long Beach, California 90808, United States
  • Regeneron Research Site
    Mission Viejo, California 92691, United States
  • Regeneron Research Site
    Rolling Hills Estates, California 90274, United States
  • Regeneron Research Site
    San Diego, California 92123, United States
  • Regeneron Research Site
    Denver, Colorado 80206, United States
  • Regeneron Research Site
    Coral Gables, Florida 33146, United States
  • Regeneron Research Site
    Tampa, Florida 33612, United States
  • Regeneron Research Site
    Tampa, Florida 33624, United States
  • Regeneron Research Site
    Macon, Georgia 31217, United States
  • Regeneron Research Site
    Sandy Springs, Georgia 30328, United States
  • Regeneron Research Site
    Chicago, Illinois 60611, United States
  • Regeneron Research Site
    Normal, Illinois 61761, United States
  • Regeneron Research Site
    Rockville, Maryland 20850, United States
  • Regeneron Research Site
    Ypsilanti, Michigan 48197, United States
  • Regeneron Research Site
    Minneapolis, Minnesota 55402, United States
  • Regeneron Research Site
    Saint Louis, Missouri 63104, United States
  • Regeneron Research Site
    Forest Hills, New York 11375, United States
  • Regeneron Research Site
    New York, New York 10029, United States
  • Regeneron Research Site
    Rochester, New York 14620, United States
  • Regeneron Research Site
    Gahanna, Ohio 43230, United States
  • Regeneron Research Site
    Portland, Oregon 97239, United States
  • Regeneron Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Regeneron Research Site
    Charleston, South Carolina 29425, United States
  • Regeneron Research Site
    North Charleston, South Carolina 29420, United States
  • Regeneron Research Site
    Bellaire, Texas 77401, United States
  • Regeneron Research Site
    San Antonio, Texas 78218, United States
  • Regeneron Research Site
    Norfolk, Virginia 23502, United States
  • Regeneron Research Site
    Seattle, Washington 98105, United States
  • Regeneron Research Site
    Calgary, Alberta T2G 1B1, Canada
  • Regeneron Research Site
    Markham, Ontario L3P 1X2, Canada
  • Regeneron Research Site
    Peterborough, Ontario K9J 5K2, Canada
  • Regeneron Research Site
    Montréal, Quebec H3T 1C5, Canada
  • Regeneron Research Site
    Kutná Hora, 284 01, Czechia
  • Regeneron Research Site
    Ústí Nad Labem, 40113, Czechia
  • Regeneron Research Site
    Muenchen, Bavaria 80337, Germany
  • Regeneron Research Site
    Osnabruck, Lower Saxony 49074, Germany
  • Regeneron Research Site
    Munster, Nordrhein-Westfalen 48149, Germany
  • Regeneron Research Site
    Dresden, Sachsen 01307, Germany
  • Regeneron Research Site
    Gera, Thuringen 07548, Germany
  • Regeneron Research Site
    Bad Bentheim, 48455, Germany
  • Regeneron Research Site
    Hamburg, 22149, Germany
  • Regeneron Research Site
    Wroclaw, Dolnoslaskie 50381, Poland
  • Regeneron Research Site
    Krakow, Malopolska 30363, Poland
  • Regeneron Research Site
    Białystok, 15-453, Poland
  • Regeneron Research Site
    Bydgoszcz, 85-065, Poland
  • Regeneron Research Site
    Gdańsk, 80-152, Poland
  • Regeneron Research Site
    Katowice, 40-611, Poland
  • Regeneron Research Site
    Katowice, 40-648, Poland
  • Regeneron Research Site
    Katowice, 40123, Poland
  • Regeneron Research Site
    Warszawa, 01-142, Poland
  • Regeneron Research Site
    Warszawa, 01-817, Poland
  • Regeneron Research Site
    Warszawa, 02-758, Poland
  • Regeneron Research Site
    Łódź, 90-265, Poland
  • Regeneron Research Site
    Świętokrzyskie, 27-400, Poland
  • Regeneron Research Site
    London, SE1 7EH, United Kingdom
  • Regeneron Research Site
    Manchester, M13 9WL, United Kingdom
  • Regeneron Research Site
    Newcastle Upon Tyne, NE1 4LP, United Kingdom
  • Regeneron Research Site
    Sheffield, S10 2TH, United Kingdom
09

References and documents

Publications

  • Paller AS, Yosipovitch G, Weidinger S, DiBenedetti D, Whalley D, Gadkari A, Guillemin I, Zhang H, Eckert L, Chao J, Bansal A, Chuang CC, Delevry D. Development, Psychometric Validation and Responder Definition of Worst Itch Scale in Children with Severe Atopic Dermatitis. Dermatol Ther (Heidelb). 2022 Dec;12(12):2839-2850. doi: 10.1007/s13555-022-00804-z. Epub 2022 Oct 21. PubMed 36269504 ↗
  • Paller AS, Wollenberg A, Siegfried E, Thaci D, Cork MJ, Arkwright PD, Gooderham M, Sun X, O'Malley JT, Khokhar FA, Vakil J, Bansal A, Rosner K, Shumel B, Levit NA. Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial. Paediatr Drugs. 2021 Sep;23(5):515-527. doi: 10.1007/s40272-021-00459-x. Epub 2021 Aug 31. PubMed 34462864 ↗
  • Simpson EL, Paller AS, Siegfried EC, Thaci D, Wollenberg A, Cork MJ, Marcoux D, Huang R, Chen Z, Rossi AB, Shumel B, Sierka D, Bansal A. Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older. Dermatol Ther (Heidelb). 2021 Oct;11(5):1643-1656. doi: 10.1007/s13555-021-00568-y. Epub 2021 Aug 24. PubMed 34427891 ↗
  • Kamal MA, Kovalenko P, Kosloski MP, Srinivasan K, Zhang Y, Rajadhyaksha M, Lai CH, Kanamaluru V, Xu C, Sun X, Simpson EL, Paller AS, Siegfried EC, Shumel B, Bansal A, Al-Huniti N, Davis JD. The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis. Clin Pharmacol Ther. 2021 Nov;110(5):1318-1328. doi: 10.1002/cpt.2366. Epub 2021 Aug 24. PubMed 34270797 ↗
  • Simpson EL, de Bruin-Weller M, Bansal A, Chen Z, Nelson L, Whalley D, Prescilla R, Guillemin I, Delevry D. Definition of Clinically Meaningful Within-Patient Changes in POEM and CDLQI in Children 6 to 11 Years of Age with Severe Atopic Dermatitis. Dermatol Ther (Heidelb). 2021 Aug;11(4):1415-1422. doi: 10.1007/s13555-021-00543-7. Epub 2021 May 27. PubMed 34046851 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jun 2019, 19 months.

Results were first posted in Aug 2020, 1 year 1 month after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 19 months is close to that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2017
First posted
Nov 17, 2017
StartActual
Nov 17, 2017
Primary completionActual
Jun 20, 2019
CompletionActual
Sep 10, 2019
Results first posted
Aug 13, 2020
Last update
Aug 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03345914
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Nov 17, 2017
Primary completion
Jun 20, 2019
Completion
Sep 10, 2019
Results posted
Aug 13, 2020
Last update
Aug 13, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion